Getting new treatments approved has never been harder, but recent research reveals that the regulatory agency has also never been faster. So why is it getting more expensive and taking ever longer to bring a treatment to market? Three words: Clinical trial delays.
It’s taking longer to bring a treatment to
When sponsors and contract research organizations (CROs) make decisions about which sites to include in a clinical trial, they too often rely on outdated historical data and show little confidence in the additional data the sites provide to them.
For example, when completing the traditional site feasibility assessment sites may guess
The principal investigator (PI) meeting is a well-established (and expensive) tradition in the pharmaceutical industry. And, in our era of global programs, you might need to host multiple PI meetings: one for the Americas, one in Europe, one in Asia. Yet, no matter how many meetings you host, you will
One of the best analogies on learning that I ever learned came in a rather unlikely place.
I had just walked from my car to meet a PGA Top 100 golf instructor (John Dunigan), he was going to help me work through some issues with my game. 15 minutes into the